AcquisitionsMay 29, 2026, 07:46 AM
SciSparc Subsidiary NeuroThera Gets Conditional Approval for CliniQuantum Acquisition
AI Summary
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., received conditional regulatory approval from the TSX Venture Exchange for the acquisition of approximately 54% interest in CliniQuantum Ltd. The acquisition involves NeuroThera issuing 56,600,000 common shares, valued at approximately $9.46 million, to CliniQuantum's selling shareholders. An amendment to the Share Purchase Agreement also established a minimum price of $0.05 per share for earn-out payments and extended the transaction completion date to June 1, 2026, to finalize closing conditions.
Key Highlights
- NeuroThera Labs received conditional regulatory approval from TSX Venture Exchange for the acquisition of CliniQuantum.
- NeuroThera will acquire approximately 54% interest in CliniQuantum.
- Consideration for the acquisition is 56,600,000 common shares of NeuroThera, valued at approximately $9,459,954.20.
- An amendment to the Share Purchase Agreement sets a minimum price of $0.05 per common share for earn-out payments.
- The completion date for the transaction has been extended from April 30, 2026, to June 1, 2026.
- CliniQuantum develops a platform applying quantum simulation to clinical trial data analysis.
- Selling Shareholders will deposit Consideration Shares into escrow per TSX policies.
Price Impact
More from SPRC